Edesa Biotech Inc
EDSA
Company Profile
Business description
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Contact
100 Spy Court
MarkhamONL3R 5H6
CANT: +1 289 800-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
16
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 2.50 | 0.03% |
| CAC 40 | 8,170.09 | 0.00 | 0.00% |
| DAX 40 | 23,876.55 | 165.07 | -0.69% |
| Dow JONES (US) | 47,147.48 | 309.74 | -0.65% |
| FTSE 100 | 9,698.37 | 109.31 | -1.11% |
| HKSE | 26,572.46 | 500.57 | -1.85% |
| NASDAQ | 22,900.59 | 30.23 | 0.13% |
| Nikkei 225 | 50,376.53 | 905.30 | -1.77% |
| NZX 50 Index | 13,464.46 | 133.41 | -0.98% |
| S&P 500 | 6,734.11 | 3.38 | -0.05% |
| S&P/ASX 200 | 8,634.50 | 8.90 | 0.10% |
| SSE Composite Index | 3,990.49 | 39.01 | -0.97% |